UCART-20x22

N/A

Report date: 2024/03/22 20:01:55

Base Information

Drug NameUCART-20x22

Drug Alias NameUCART-20x22

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionAnti-CD20Anti-CD22

TargetsB-lymphocyte antigen CD20CD22

Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFranceSpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCellectis Sa

China Registration ClassN/A

Develop Information

Active CompaniesCellectis Sa

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A